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Abstract
Introduction: Male breast cancer (MBC) is a rare, yet potentially aggressive disease. Although literature regarding
female breast cancer (FBC) is extensive, little is known about the etiopathogenesis of male breast cancer. Studies
from our laboratory show that MBCs have a distinct immunophenotypic profile, suggesting that the
etiopathogenesis of MBC is different from FBCs. The aim of this study was to evaluate and correlate the
immunohistochemical expression of cell cycle proteins in male breast carcinoma to significant clinico-biological
endpoints.
Methods: 75 cases of MBC were identified using the records of the Saskatchewan Cancer Agency over 26 years
(1970-1996). Cases were reviewed and analyzed for the immunohistochemical expression of PCNA, Ki67, p27, p16,
p57, p21, cyclin-D1 and c-myc and correlated to clinico-biological endpoints of tumor size, node status, stage of
the disease, and disease free survival (DFS).
Results: Decreased DFS was observed in the majority of tumors that overexpressed PCNA (98%, p = 0.004). The
overexpression of PCNA was inversely correlated to the expression of Ki67 which was predominantly negative
(78.3%). Cyclin D1 was overexpressed in 83.7% of cases. Cyclin D1 positive tumors were smaller than 2 cm (55.6%,
p = 0.005), had a low incidence of lymph node metastasis (38.2%, p = 0.04) and were associated with increased
DFS of >150 months (p = 0.04). Overexpression of c-myc (90%) was linked with a higher incidence of node
negativity (58.3%, p = 0.006) and increased DFS (p = 0.04). p27 over expression was associated with decreased
lymph node metastasis (p = 0.04). P21 and p57 positive tumors were related to decreased DFS (p = 0.04). Though
p16 was overexpressed in 76.6%, this did not reach statistical significance with DFS (p = 0.06) or nodal status (p =
0.07).
Conclusion: Aberrant cell cycle protein expression supports our view that these are important pathways involved
in the etiopathogenesis of MBC. Tumors with overexpression of Cyclin D1 and c-myc had better outcomes, in
contrast to tumors with overexpression of p21, p57, and PCNA with significantly worse outcomes. P27 appears to
be a predictive marker for lymph nodal status. Such observation strongly suggests that dysregulation of cell cycle
proteins may play a unique role in the initiation and progression of disease in male breast cancer. Such findings
open up new avenues for the treatment of MBC as a suitable candidate for novel CDK-based anticancer therapies
in the future.
Introduction
Male breast cancer (MBC) remains a rare yet potentially
fatal disease, accounting for less than 1% of mammary
neoplasia [1-4] and 0.17% of all tumors in men [5], yet
this number is rising [2,6,7]. While the incidences of
MBC in North America and Western Europe remain
low, the proportion of MBC cases is as high as 15% in
sub-Saharan Africa [6]. The majority of the baseline
knowledge and treatment protocols of male breast can-
cers are largely extrapolated from the treatment and
behavior of female breast cancers (FBC) [1,7] as MBC
behaves similarly to FBC in post-menopausal women
[8]. The prevalence of MBC increases with age and the
presentation occurs at an average age of 60 years, a dec-
ade later than in females. The majority of patients pre-
sent with a painless, firm subareolar mass, tumors
usually larger than 2 cm in diameter, and there may be
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any medium, provided the original work is properly cited.fixation to skin. Pathologically, invasive ductal carci-
noma (93.7%) is the predominant subtype, and lobular
carcinoma is rare (1.8%) [5,9]. Nevertheless invasive
ductal carcinoma of MBC is distinctly different from
that in females in both presentation and immunopheno-
type [10]. Risk factors of MBC include testicular disease,
benign breast conditions, age, Jewish ancestry, family
history, liver disease, obesity, electromagnetic field radia-
tion, infertility, and the strongest association being Kli-
nefelters syndrome [7,11].
Due to the rarity of MBC, limited information is avail-
able [1,3]. Typically men with breast cancer have a
longer duration of symptoms than women [12]. With a
lack of awareness and the advanced stage at presenta-
tion, such delay in diagnosis often causes a worse prog-
nosis than FBC [13]. Consequently MBC patients have a
mortality of 5-10 years in 36-75% of cases [13]. Because
of uninformed population, the need to implement
means of communication to notify males and urge ima-
ging studies is greatly important as a means to lower
the risk of worse prognosis in MBC [5]. This risk is
further amplified as men with breast cancer have a sig-
nificantly higher risk for a secondary malignancy in
comparison with the general population [13].
Studies in our laboratory confirm that male breast
cancers display distinct immunophenotypic differences
in comparison to female breast cancers [1]. The male
breast cancers despite being high-grade neoplasms
remain estrogen and progesterone receptor positive and
cerbB2 and p53 negative [1]. Thus, it is postulated that
alternative pathways of carcinogenesis are involved in
the development and progression of male breast cancers
[1]. Such pathways may implicate cell cycle dysregula-
tion, apoptosis, growth factor pathway and/or androgen
receptor pathway [1]. Deregulation of cell cycle control
is central to our understanding of the development and
progression of all human malignancies [14]. These pro-
teins that play key roles [15-18] in the cell cycle regula-
tion have therefore been the interest of our current
study. We investigated the expression of CyclinD1,
PCNA, c-myc, Ki67, p21, p27, p57, p16 and correlated
the expression level of these factors with clinicopatholo-
gical factors, such as lymph node status, tumor size,
stage of the disease and disease free survival, as in many
female breast cancer studies these four clinico-patholo-
gical parameters have proven to be of high prognostic
value [16,18]. Additionally, we compared the outcomes
of our study with results, found in the published litera-
ture about female breast cancer, to see if there are any
major trends, which are unique to male breast cancer.
The overall goal of this study was to fill major gaps in
knowledge regarding the role of the cell cycle proteins
in the etiopathogenesis of male breast cancer. This
study is an extension of our established work on
immunophenotypic characterization and angiogenesis in
male breast cancer in Saskatchewan [1,10].
Materials and methods
Seventy-five cases of primary male breast cancers were
identified using the records of the Saskatchewan Cancer
Agency over a period of 26 years (1970-1996). The clini-
copathological profiles of these cases are identical to the
previous published data from our laboratory [Additional
file 1]. 59 of these cases had formalin fixed, paraffin
embedded tissue blocks available for the purposes of
this study. All cases were reviewed and graded according
to Bloom-Richardson criteria for female breast cancers
on a routine hematoxylin-eosin-stained slide.
Immunohistochemical studies were performed on a
representative deparaffinized tissue section by the avi-
din-biotin-peroxidase (ABC) technique after antigen
retrieval using appropriate positive and negative controls
in all cases. Negative controls were obtained by omis-
sion of the primary antibody from the staining proce-
dure. The antibodies used with their sources and
dilutions are listed in Table 1. The immunohistochem-
ical expression of PCNA, Ki67, p27, p16, p57, p21,
cyclin-D1 and c-myc were analyzed on a semi-quantita-
tive basis. As seen in figure 1, each slide was rated on a
four-point scale: 0, no stain (up to 10% positive cells); 1,
light (11-25% positive cells); 2, moderate (26-50% posi-
tive cells); 3, heavy (51-75% positive cells); 4, intense
stain (76-100% positive cells). The cells were considered
positive when more than 10% of them were stained with
the respective antibodies.
Statistical analysis using the Statistical Package for the
Social Sciences (SPSS) version 16 compared the immu-
nohistochemical expression of these proteins to the fol-
lowing prognostic clinico-biological parameters: a) nodal
status (Figure 2), b) stage of the disease (Figure 3), c) of
tumor size (Figure 4), and d) disease free survival (Fig-
u r e5 ) .D i s e a s ef r e es u r v i v a l( D F S )w a sd e f i n e da st h e
interval between primary treatment to the first recur-
rence or death. Statistical significance of the
Table 1 Antibodies examined in this study.
ANTIBODY CLONE DILUTION SOURCE
PCNA PC10 prediluted Ventana
Ki67 MIB-1 1/100 Immunotech
p27 SX53G8 1/20 Dako
p16 F-12 1/75 Oncogene
p57 25B2 1/25 Novacastra
p21 EA10 1/5 Oncogene
cyclin-D1 P2D11F11 prediluted Ventana
c-myc 9E11 1/200 Novacastra
This table lists the antibodies used in this study with clone, dilution ratio, and
source.
Kanthan et al. World Journal of Surgical Oncology 2010, 8:10
http://www.wjso.com/content/8/1/10
Page 2 of 11immunohistochemical scores were calculated using the
Fisher’s exact test. Statistical significance of the differ-
ences between the cases demonstrating positive and
negative cell cycle protein expression in each of the clin-
icobiological parameter assessed was calculated using
the two sample Student’st-test. A P-value of less than
0.05 was considered statistically significant.
This study was conducted with ethics approval from
the University of Saskatchewan Advisory Committee on
Human Experimentation.
Results and discussion
Management protocols for male breast cancer patients
have been modeled on traditional female breast cancer
treatment regimes. However, it is becoming more appar-
ent with increased work in this area that the male breast
cancers do not seem to behave similar to female breast
cancers. Study of male breast cancers in our own labora-
tory has revealed that despite the majority of these neo-
plasms being high-grade cancers, they retain the
expression of estrogen and progesterone receptor anti-
bodies and are also less likely to over express Erb-B2
and/or p53 in contrast to high grade female breast can-
cers. This therefore surmises that the current pathways
of treatment protocols applicable in women that are
directly linked to ER up-regulation leading to activation
of downstream targets such as p53 and/or Erb-B2 does
not hold validity in the case of male breast cancers.
Thus, alternative pathways such as cell cycle dysregula-
tion or androgen receptor alterations are perhaps
involved in the development and evolution of male
breast cancer. As deregulation of cell cycle control is
central to our understanding of the development and
progression of all human malignancies [14], this was
explored in our laboratory in this study protocol.
Cell Cycle
The cell cycle is a defined set of phases and checkpoints
through which a proliferating cell must pass prior to
division. As illustrated in figure 6 the four phases are
gap 1 (G1), synthesis (S), mitosis (M) and gap 2 (G2). In
the G1 phase, the cell grows in preparation for DNA
synthesis. It follows therefore that the subsequent phase,
the S phase, is where DNA synthesis occurs. After this,
the cell goes through the second gap phase, where the
cell grows in preparation for its physical division. This
division occurs in the M phase. After division, the
daughter cells may continue proliferating by entering
the G1 phase; alternatively, the cell may enter a fifth
phase labeled G0.I nG 0, cells are quiescent (non-divid-
ing); G0cells may experience cessation of proliferation
temporarily or in permanence. There are three impor-
tant checkpoints: G1, G2,a n dmetaphase.A tt h eG 1
checkpoint, mechanisms verify that the cell has grown
sufficiently and that the environment is suitable for
DNA synthesis. At the G2 checkpoint, mechanisms
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Figure 1 Percentage of Cell cycle protein expression in the tumor cells. X-axis displays: the expression of the cell cycle proteins CyclinD1,
p21, Ki67, PCNA, p16, p27, p57, and c-myc. Y-axis displays: the percentage of positive stained cells in the tumor, where: 0 = no stain, up to 10%
positive cells. 1 = light stain, 11-25% positive cells. 2 = moderate stain, 26-50% positive cells. 3 = heavy stain 51-75% positive cells. 4 = intense
stain 76-100% positive cells.
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Figure 2 Cell cycle protein expression in Node positive and Node negative tumors. X-axis displays: the expression of positive and negative
tumors for cell cycle proteins CyclinD1, p21, Ki67, PCNA, p16, p27, p57, and c-myc. Y-axis displays: the node negative and node positive tumors.
Statistical significance * p < 0.05.
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
C
y
c
 
D
1
 
-
C
y
c
 
D
1
+
P
2
1
 
-
P
2
1
 
+
K
i
6
7
 
-
K
i
6
7
 
+
P
C
N
A
 
-
P
C
N
A
 
+
P
1
6
 
-
P
1
6
 
+
P
2
7
 
-
P
2
7
 
+
P
5
7
 
-
P
5
7
 
+
c
m
y
c
 
-
c
m
y
c
 
+
Cell Cycle Proteins
P
e
r
c
e
n
t
a
g
e
stage 1
stage 2
stage 3
stage 4
Figure 3 Cell cycle protein expression and Stage of the disease. X-axis displays: the expression of positive and negative tumors for cell cycle
proteins CyclinD1, p21, Ki67, PCNA, p16, p27, p57, and cmyc. Y-axis displays: the four stages of disease. Statistical significance * p < 0.05.
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Page 4 of 11verify that the DNA has successfully replicated, that the
cell is big enough and that the environment is suitable
for actual cell division. The metaphase checkpoint veri-
fies that the chromosomes are aligned on the spindle
during mitosis. If these conditions cannot be satisfied at
their respective checkpoints, there is cessation of the
cell cycle. Cells regulate growth through complex signal-
ing pathways that act to maintain and integrate
sequence of DNA replication (DNA synthesis, S-phase)
that precedes mitosis in the cell cycle. Cyclin-dependent
kinase enzymes (CDKs) determine cell cycle prolifera-
tion, such that their activation depends on an associa-
tion with a phase specific protein. DNA damage
activation of “checkpoints” ensure genomic integrity
through inhibition of CDKs to effect a cell cycle arrest
and repair prior to replication (G1 checkpoint), or
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
C
y
c
 
D
1
 
-
C
y
c
 
D
1
+
P
2
1
 
-
P
2
1
 
+
K
i
6
7
 
-
K
i
6
7
 
+
P
C
N
A
 
-
P
C
N
A
 
+
P
1
6
 
-
P
1
6
 
+
P
2
7
 
-
P
2
7
 
+
P
5
7
 
-
P
5
7
 
+
c
m
y
c
 
-
c
m
y
c
 
+
Cell Cycle Proteins
P
e
r
c
e
n
t
a
g
e
< 2cm
2-5 cm
> 5cm
* 
Figure 4 Cell cycle protein expression and Tumor Size. X-axis displays: the expression of positive and negative tumors for cell cycle proteins
CyclinD1, p21, Ki67, PCNA, p16, p27, p57, and cmyc. Y-axis: the tumor size data includes: less than 2 cm, 2-5 cm, and more than 5 cm. Statistical
significance * p < 0.05.
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Figure 5 Cell cycle protein expression and the Disease Free Survival (DFS, counted in months). X-axis displays: the expression of positive
and negative tumors for cell cycle proteins CyclinD1, p21, Ki67, PCNA, p16, p27, p57, and cmyc. Y-axis displays: the duration of disease free
survival (DFS, counted in months). Statistical significance * p < 0.05.
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Page 5 of 11mitosis (G2 checkpoint), with apoptosis constituting an
alternative pathway of eliminating DNA damaged cells.
Loss of “checkpoint functions” is a hallmark of many
human cancers where there is replication and segrega-
tion of damaged DNA. P21 functions as a universal
cyclin-dependent kinase inhibitory protein (CDK1) with
an affinity for G1 and G2 cyclin-CDK complexes, thus
acting as “checkpoint proteins” at the G1 and G2 levels
(figure 6).
The molecular machinery which controls the cell cycle
relies on a delicate balance between factors supporting
growth and factors supporting stasis. The growth (or
lack thereof) we observe by an individual cell is a reflec-
tion of the net sum of all growth promoting and inhibit-
ing factors in its local environment. The factors of
interest in this study are cyclin-D1, PCNA, Ki67, p16,
p21, p27, p57 and c-myc.
Cyclin-D1
Cyclins are responsible for controlling entry and pro-
gression through the cell cycle, specifically regulating
the G1-S phase transition (figure 6). Induction of this
cyclin shortens the G1 phase and consequently increases
the number of cells passing through this checkpoint
[19,20]. These proteins complex with (and thus activate)
cyclin-dependant kinases (CDKs). Varying levels of dif-
ferent cyclins and CDKs are associated with progression
through each of the important transitions in the cell
cycle, and can be associated to tumor grade [21]. Cyclin
D 1a c t sa so n eo ft h em o s tc o m m o n l yo v e r e x p r e s s e d
oncogenes in breast cancer, found in 30-60% of primary
ductal adenocarcinoma and universally overexpressed in
lobular carcinomas [22,23]. The effects exerted by these
diverse proteins include: altering activity of enzymes,
altering affinity between proteins, altering affinity
between protein and DNA, altering the metabolism of
proteins. What effect a CDK may have depends not only
on the protein itself, but also the environment, and the
substrates involved [14,24-27].
Aberrant expression of cyclinD1 protein is a common
feature in female breast cancers [24-27]. As a result of
alternative splicing of the transcript CCND1, two iso-
forms of cyclin D1 exist: the conventional cyclin D1a and
cyclin D1b [28]. In FBCs while high cyclin D1a levels are
not associated with recurrence or metastases, high cyclin
D1b levels are associated with poor survival and can pre-
dict disease outcomes. High cyclin D1a are found predo-
minantly in ER-positive tumors and are inversely
correlated with Ki67 with little impact on disease out-
come. In contrast, elevated cyclin D1b expression was
independently associated with adverse clinical outcomes
including recurrence, distant metastasis and decreased
s u r v i v a lt h e r e b yi d e n t i f y i n gau n i q u es u b s e to ft u m o r s
associated with increased disease progression [28].
In our study 83.7% of the cases were positive for
cyclin-D1 overexpression (figure 1). Proven by several
studies, female breast cancers also show high expression
of Cyclin D1 [[14] (28%), [24](48.3% >5%), [25](59%
>5%), [27,29] (65% >5%), [30] (66.7% >10%), [31,32]].
Cyclin D1 positive tumors seemed to be less likely asso-
ciated with lymph node metastasis (38.2% vs. 57.1% in
cyclin D1 negative tumors at p = 0.04, figure 2). This is
in contrast to studies in female breast cancer that do
not find a statistical significant correlation between
cyclin D1 and metastatic disease and axillary lymph
node involvement [19,25,29], yet there was an associa-
tion between the expression of cyclin D1b and distant
metastasis [28]. There was a strong tendency for cyclin
D1 positive male breast tumors to be smaller than 2 cm
[25,29] (55.6% vs. 14.3% of cyclin D1 negatives at p =
0.005, figure 4). Female breast cancers do not seem to
have this correlation [25,29]. There was no correlation
of CyclinD1 overexpression and the stage of the disease
(figure 3). As seen in figure 5, none of the patients hav-
ing a CyclinD1 negative tumor had a DFS over 150
months, in comparison to 18.4% in the CycD1 positive
group (p = 0.04). In the published literature this is con-
troversial and inconclusive. In some studies no correla-
tion between CyclinD1 and DFS could be found
[14,19,26] while Gillet et al has shown moderate/strong
staining for CyclinD1 was associated with improved DFS
and overall survival relative to tumors that stained
weakly or negatively[32]. Yet negative Cyclin D1 tumors
had an adverse prognosis with poor outcomes especially
if they were ER negative tumors as well [33]. Our study
shows that negative Cyclin D1 tumors are associated
with adverse prognosis of increased incidence of lymph
node metastasis, larger tumors, and decreased DFS.
PCNA
Proliferating cell nuclear antigen (PCNA) is a protein
which forms a ring around a portion of DNA serving to
anchor various DNA replication and repair proteins and
regulates proliferation throughout the cell cycle [34-36]
(figure 6). PCNA expression was elevated in our study
in 98% of the cases, with 67.4% showing intensive stain-
ing (figure 1). Due to the low percentage of PCNA nega-
tive cases, a comparison of the clinicopathological
parameters between the positive and negative group was
not feasible. This elevated expression of PCNA is also
seen in studies on female breast cancers, where 71.4%-
100% of cases were considered PCNA positive [17,37]
Mean proliferating index was 76.1%, with a range from
0-100%. Compared to results in female breast cancer,
t h i sv a l u es e e m st ob ef a ra b o v et h er a n g eo fr e s u l t s
reported by others (10.2% -28.7%) [34]. In the female
breast cancer literature the correlation between the
range of proliferating indexes [PI] and classical
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controversial. Some authors found strong, statistically
significant correlation between PI, PCNA or Ki67 level
and tumor size or nodal status [34]. The majority of
investigators however, think that such relationship do
not exist [34]. In our study in male breast cancer the
PCNA was positive in 55.3% of node negative tumors
and 44.7% of node positive tumors, p = 0.0001(figure 2).
As far as size of the tumor was concerned no significant
statistical significance could be found with 47.6% posi-
tive PCNA expression in tumors with a size less than 2
cm (figure 4). However, PCNA overexpression was
associated with decreased DFS (98%, p = 0.004) indicat-
ing perhaps disease progression with increased adverse
clinical outcome.
C-myc
The c-myc gene is amplified and/or overexpressed in
different frequencies in most human malignancy [38],
though amplification occurs more frequently in metas-
tases than in primary tumors [39]. A regulator of a cell’s
size and participant in cellular functioning such as
growth, differentiation, apoptosis, and metabolism [38],
this oncogene can both activate and repress specific
Figure 6 Schematic illustration of the regulatory proteins in the cell cycle phases. The cell cycle is illustrated (outer blue circle)
schematically through its various phases–G1/S, G2/M. (G1 = growth phase 1; S = synthesis; G2 = growth phase 2; M = mitosis). The proteins
studied are color coded to the most prominent phase of their action in the cell cycle: Cyclin D1 is green, G1. p21, p27, p57 are orange, S/G2. p16
is violet, G1. Ki67 (coral) and PCNA (brown) all phases. P53 is black, checkpoint G2/M. The insert are two photomicrographs of the
immunohistochemical expression of p27 and p16 in the malignant breast cancer cells at a medium magnification ×150.
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vates transcription for many growth related genes
(including CDKs). The myc protein is induced when a
cell is stimulated to pass from the quiescent G0 state to
the active G1 state. The normal myc gene is a protoon-
cogene, thus, when it becomes dysregulated (mutation
or other) it promotes uncontrollable cell division [40].
In our study of male breast cancer, c-myc was expressed
in 90% of the cases (figure 1). Several critical issues
regarding the significance of c-myc in human breast
cancer still remain obscure. The frequencies of the
expression levels vary greatly from one report to another
(50-100%) [40]. In our study the percentage of cases
being node negative seemed to be lower in c-myc nega-
tive cancers (20% vs. 58.3%, p = 0.006) in c-myc posi-
tives) as demonstrated in figure 2.
In a female breast cancer study on node negative
tumors done by Schlotter, c-myc amplification appears
to represent a prognostic marker to predict early recur-
rence [41]. Pich et al has reported a 107 month survival
for c-myc negative cases and 52 months for c-myc posi-
tive male breast cancer patients [42]. As seen in figure
5, in our study all c-myc negative tumors had a DFS
lower than 100 months, with only one living longer than
50 months(p = 0.04). There was no statistically signifi-
cant association between c-myc protein levels and stage
of the disease as seen in figure 3. Though not statisti-
cally significant, p = 0.08, 55% of tumors >2 cms were
c-myc positive in our study (figure 4). Interestingly, Aul-
mann et al, 2002 using FISH and focusing on DCIS,
detected amplification of c-myc in only 20% of the
cases, but found a correlation of c- myc with increased
tumor size and proliferation [40]. Further, In FBCs, high
C-myc expression levels are correlated on one hand
with larger sizes tumors but on the other hand with bet-
ter survival [38]. Similar parallel trends are seen in our
study, wherein c-myc overexpression though associated
with larger tumor size, had lower incidence of lymph
node metastasis and better DFS indicating a favorable
prognosis.
Ki-67
Ki67 nuclear antigen is associated with cell prolifera-
tion and is found throughout the cell cycle except the
Go phase [16,35,43](figure 6) and has become recog-
nized as a proliferation marker in breast cancer [44]
where a higher percentage correlates with an increase
in tumor grade[45]. In our study Ki67 expression was
mostly negative (78.3%, figure 1). This is in contrast to
high grade FBC with high Ki67 expression in 95% of
the cases [37]. Within the numbers of tumors consid-
ered positive for Ki67 expression, the proliferating
index (PI) ranged from 0%-40%, leading to a mean PI
of 6.6%. The mean PI so falls within the range of
values reported by others studying female breast can-
cers (6%-22%) [34,35]. In our study Ki67 negative cases
had a higher tendency of being node negative (65.5%
vs. 50% in positive cases, figure 2). Furthermore there
was a trend of Ki67 negative tumors, having a size less
than 2 cm with 54.8% of the Ki67 negative tumors
being smaller than 2 cm, whereas only 25% of the Ki67
positives were of similar size. Though not statistically
significant, in our study Ki67 positive tumors seemed
to be associated with larger tumor size as seen in fig-
ure 4. This finding is congruent with literature stating
20-40% of MBC cases are positive for Ki-67 and when
combine with androgen receptor negativity tend
towards worse prognosis [45]. In female breast cancers,
some authors found strong, statistically significant cor-
relation between PI, PCNA or Ki67 level and tumor
size as well as nodal status [34]. As already mentioned
the majority of investigators, think that such relation-
ship does not exist [16,36,37,43]. In this study the
mean PI node negative male breast tumors was 2.73%
(range 0%-10%) and 7.7% (range 0%-30%) in node posi-
t i v e s( f i g u r e2 ) .T u m o r sw i t has i z el e s st h a n2c mh a d
an IP of 3.95% (range 40%-100%) and those larger than
2 cm one of 9.3% (range 0%-40%). Remarkable is also
the inverse correlation between Ki67 and PCNA within
the tumors of this study. Also in studies about female
breast cancer some authors have found a similar lack
of correlation between the two indices [35,36]. Yet
there are also studies that report the opposite. No sig-
nificant correlations were observed between the Ki67
expression levels and tumor stage (figure 3) and DFS
as demonstrated in figure 5. In our study, Ki67 does
not appear to play a dominant role in disease progres-
sion or survival in male breast cancer.
p21, p27, p57, p16
These proteins are part of the CDKN1A family; a family
of proteins which broadly inhibits the activity of CDKs.
As illustrated in figure 6 these proteins act as a brake
for cell proliferation; their expression contributing to a
cessation in the cell cycle, especially during the S and
G2 phases [15,18,33,46,47].
p21 remained negative in 58.7% of our male breast
cancer cases(figure 1). As other studies showed, there
was no significant difference in this point concerning
the female counterpart [46]. In our study 94.4% of
tumors showing a p21 expression had a DFS shorter
than 150 months (vs. 74% in the negative group, p =
0 . 0 4 )a ss e e ni nf i g u r e5 .T h i st r e n do fp 2 1n e g a t i v i t y
combined with a longer disease free survival in our
cases of male breast cancer has also seen in a study of
female breast cancer [48]. In another existing study the
immunohistochemical expression of p21 was analyzed
and compared between 27 cases of primary male breast
Kanthan et al. World Journal of Surgical Oncology 2010, 8:10
http://www.wjso.com/content/8/1/10
Page 8 of 11cancer (MBC) and 101 cases of female breast cancer
(FBC). A statistically significant difference in the immu-
nostaining of p21 in male patients compared with
females was found. Expression of p21Waf1 was observed
in 19 of the 27 primary MBC (70.3%) vs. 29 of 101 FBC
(29%) [47]. André et al has demonstrated the occurrence
of p21-positive is significantly higher in MBC than FBC
(FBC: 58% positive 42% negative vs. MBC: 4% negative
96% positive) [49]. This further strengthens the view
that MBC and FBC probably have distinct tumor onco-
genesis. The exact biological role of p21 expression
remains unclear as there is no evidence of strong corre-
lation with other cell cycle regulatory proteins or Ki-67
[49]. Yet, overall p21 positivity is associated with adverse
outcomes as it is associated with decreased DFS.
p27 is a CDK inhibitor required for entry to S-phase.
Loss of p27 is believed to contribute to oncogenesis
[47]. Most often associated with cell cycle arrest
[47,50], p27 maintains CDKs in an inactive state and
thus blocks entry to the S-phase [51] and in tumors
with a high estrogen receptor expression and low S-
phase fraction has a high expression [47]. The level of
p27 is not stagnant: the level rises as the cells exit the
cell, proteolysis causes the levels to drop, and can be
inactivated by cyclin sequestering [50]. P27 overexpre-
sion in MBC could reflect a failing feedback attempt of
a normal protein rather than be the result of an altera-
tion in the p21 gene. Expression of p27 was noted in
81.2% of our cases (figure 1). A study about the role of
p27 in human breast cancer cell lines showed that 5
out of 12 (41.7%) of the tested cell lines showed high
level p27 expression [15]. Similar to our findings in
Curigliano’s study the immunohistochemical expres-
sion of p27 was analyzed and compared between 27
cases of primary male breast cancer (MBC) and 101
cases of female breast cancer (FBC). P27 immunoreac-
tivity was detected in 26 of 27 male breast patients
(96.2%) vs. 39 of 101 FBC (39.3%) [47]. A salient find-
ing in our study is the high percentage (85.7%) of node
negative cancers in the p27 negative group in compari-
son to 45.2% at p = 0.04 (figure 2). P27 expression in
node negative cases suggests that p27 may be a predic-
tive marker for lymph nodal status.
Expression of p57 was noted in 78.7% of our MBC
cases (figure 1). P57 positives tumors showed a slightly
higher tendency to be associated with node positivity
(57.1% vs. 40.6% of the p57 negative cases, figure 2).
As for tumor size (figure 4), 28.6% of the p57 negatives
were larger than 5 cm in comparison to 9.1% in the
p57 positive cases suggesting loss of p57 expression
being associated with larger tumor size. Tumors that
were p57 and p21 positive were associated with
decreased DFS (p = 0.04) (Figure 5) indicating adverse
outcomes.
P16
p16 belongs to the CDKN2A family of proteins, another
family of CDK inhibitors [18,52]. This family of proteins
particularly inhibits the activity of active CDK4 and
CDK6 [52]; thus, their inhibitory activity occurs primar-
ily in the G1 phase where it accumulates and inhibits
progression to the S-phase [53] (figure 6). Reduced
expression of this protein is caused by its inactivation by
deletion, mutation, or methylation [53]. Mechanisms
leading to p16 overexpression is however not well
understood. As p16 is inactivated in 85% of tumor-
derived cells lines, it is classified as a tumour suppressor
and is the second most common genetic mutation
found in breast cancer [50]. In our study 76.6% of all
tumors showed p16 expression (figure 1). Whereas this
finding is not discrepant with another study about the
expression of p16 in female breast carcinomas [52],
there are other studies where half of the breast cancers
in women failed to express p16 [18,54,55]. Neither the
presence of p16 positive nuclei nor the lack of detect-
able staining in these studies was statistically significant
with tumor size (figure 4), tumor differentiation or
nodal status (figure 2). Though the higher percentage of
large tumors >5 cms were associated with loss of p16
expression (20% vs. 6.7% in the positives) we could not
find any statistical correlation between the expression of
p16 and the DFS (p = 0.06) (figure 5), nodal status (p =
0.07) (figure 2) or the stage of the disease as demon-
strated in figure 3. Thus similar to other investigators
despite aberrant expression, the significance of the
expression of P16 in male breast cancer could not be
established [52,53,55].
Conclusion
Male breast cancer is a rare yet potentially aggressive
disease with a distinctive immunophenotype with alter-
native pathway for tumor oncogenesis distinct from
female breast cancer. The management of MBC there-
fore necessitates different treatment regimes rather than
the traditional FBC approaches. Our study confirms
aberrant expression of cell cycle proteins in male breast
cancers. Tumor cells with overexpression of Cyclin D1
and c-myc are associated with favorable outcomes while
overexpression of p21, p57, and PCNA are linked with
adverse outcomes. P27 appears to be a predictive mar-
ker for lymph nodal status. The exact role of p16
expression remains undetermined. These cell cycle pro-
tein markers may identify a unique subset of tumors
that may be associated with aggressive disease. Dysregu-
l a t i o no fc e l lc y c l ep r o t e i n sm a yp l a yau n i q u er o l ei n
the initiation and progression of disease in male breast
cancer. This opens up a new perspective for the treat-
ment of MBC as a suitable candidate for novel CDK-
based anticancer therapies in the future.
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